Regeneron (REGN) Q3 2026 Earnings Call Transcript
Regeneron reported Q3 2026 earnings, with total revenue up 36% and non-GAAP EPS up 70% YoY. Key drugs Dupixent, EYLEA HD, and Libtayo set sales records. Dupixent global sales reached $6.5B, EYLEA HD U.S. sales hit $700M, and Libtayo global sales were $550M. The company highlighted pipeline progress in neuromuscular, metabolic, and oncology areas, with potential blockbuster opportunities.
How this was made
The 30-second read
Why it matters
The call combines quantified earnings growth with multiple time-bound catalysts (FDA decision timing and planned study starts), which can change near-term expectations for revenue durability and risk-adjusted pipeline value.
Market read
Traders can use the disclosed Q3 growth figures and the stated November FDA decision and planned registrational steps to reassess near-term catalyst calendars and probability-weighted pipeline value.
What to watch
Key valuation swing factors are the probability and timing of regulatory outcomes (cemdisiran FDA decision in November) and the success of planned potentially registrational/confirmatory studies, which are not quantified in the excerpt.
Background
This is a transcript of Regeneron’s Q3 2026 earnings call, covering commercial performance, pipeline updates, and business development commentary.
Ticker impact
Regeneron reports Q3 results with revenue up 36% and non-GAAP EPS up 70%, plus pipeline catalysts including an FDA decision expected in November for cemdisiran.
Likely upward bias as the market prices in strong commercial momentum and increased probability-weighted value from upcoming regulatory and registrational milestones.
The transcript provides concrete Q3 performance figures and specific upcoming catalysts (FDA decision timing, planned pivotal/confirmatory studies), which can drive near-term repricing versus a baseline earnings-only narrative.
Market effects
Reinforces positive sentiment for large-cap biotech commercial execution and late-stage pipeline execution, particularly in immunology, ophthalmology, and oncology.
Primarily US biotech sentiment; could modestly influence broader healthcare risk appetite around earnings season.
Global sales commentary (e.g., Dupixent and EYLEA HD) may affect international biotech sentiment but is not a cross-border policy shock.
Counterpoint
Strong reported growth may be partially driven by partner commercialization dynamics (e.g., Sanofi for Dupixent/EYLEA HD), so investors may discount the durability of REGN’s earnings power versus pipeline execution risk.
Key entities
- companyRegeneron Pharmaceuticals
US-listed biotech reporting Q3 2026 results and providing pipeline and regulatory timing updates.
- companySanofi
Partner cited for Dupixent and EYLEA HD sales and commercialization responsibilities in an expanded alliance.
- drug_programcemdisiran
siRNA therapy in generalized myasthenia gravis with an FDA decision expected in November.
- productLibtayo
Oncology immunotherapy discussed with record sales and long-term Phase III c-POST data presentation.
- drug_programubamatamab
MUC16xCD3 bispecific antibody with encouraging data in advanced low grade serous ovarian carcinoma.
